PSTX Company Profile and Key Details
Poseida Therapeutics, Inc.
PSTX Stock Price Chart
Stock Price Today
Poseida Therapeutics, Inc. (PSTX) stock remained unchanged at $9.50 a share on NASDAQ. The stock opened at $9.58, fluctuating between $9.50 to $9.58 during the session.
Stock Snapshot
Stock Price History Chart
Contact Details
About Company
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC). It is also developing P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; and P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, ovarian, and other epithelial-derived cancers. In addition, the company engages in the development of P-CD19CD20-ALLO1 for B cell malignancies and other autoimmune diseases; and P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for multiple myeloma. Further, it is developing P-PSMA-ALLO1, an allogeneic CAR-T product candidate for treating mCRPC. Additionally, the company engages in the development of P-OTC-101 and P-FVIII-101 that are clinical stage liver-directed gene therapies; and other allogeneic dual CAR candidates. It has a research collaboration and license agreement with Takeda Pharmaceutical Company Limited. The company was incorporated in 2014 and is headquartered in San Diego, California.
Company Information
| Employees | 350 |
| Beta | 0.54 |
| Sales or Revenue | $64.70M |
| 5Y Sales Change% | 0% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently Asked Questions
Poseida Therapeutics, Inc. (NASDAQ: PSTX) stock price is $9.50 in the last trading session. During the trading session, PSTX stock reached the peak price of $9.58 while $9.50 was the lowest point it dropped to. The percentage change in PSTX stock occurred in the recent session was 0% while the dollar amount for the price change in PSTX stock was -.
The NASDAQ listed PSTX is part of Biotechnology industry that operates in the broader Healthcare sector. Poseida Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Sarah Thailing
Senior Director of Corporation Communications & IR
Mr. Loren Wagner
Senior Vice President of Global Operations
Dr. Devon J. Shedlock Ph.D.
Chief Scientific Officer of Cell Therapy
Dr. Eric M. Ostertag M.D., Ph.D.
Executive Chairman
Dr. Jeffrey W. Winkelman J.D., Ph.D.
Senior Vice President & Chief Patent Counsel
Mr. Mark J. Gergen J.D.
Pres, Chief Executive Officer & Chairman
Ms. Johanna M. Mylet C.P.A.
Chief Financial Officer
Mr. Harry J. Leonhardt Esq., J.D.
Gen. Counsel, Chief Compliance Officer & Corporation Sec.
Ms. Johanna M. Mylet CPA
Chief Financial Officer
Mr. Brent Warner
Pres of Gene Therapy
Ms. Kristin Martin
Chief People & Admin. Officer
Ms. Lisa Portale
Senior Vice President of Regulatory Affairs
PSTX's closing price is 408.02% higher than its 52-week low of $1.87 where as its distance from 52-week high of $9.67 is -1.76%.
Number of PSTX employees currently stands at 350.
Official Website of PSTX is: https://www.poseida.com
PSTX could be contacted at phone 858 779 3100 and can also be accessed through its website. PSTX operates from 9390 Towne Centre Drive, San Diego, CA 92121, United States.
PSTX stock volume for the day was 21.34M shares. The average number of PSTX shares traded daily for last 3 months was 1.8M.
The market value of PSTX currently stands at $925.93M with its latest stock price at $9.50 and 97.47M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com